www.rmpd.org.uk

You are here: Home > Abstracts > Radiotherapy Physics > Radiotherapy for prostate cancer

Radiotherapy for prostate cancer

Purpose: To estimate the benefits of dose escalation in hypofractionated intensity-modulated radiotherapy (IMRT) for prostate cancer, using radiobiologic modelling and incorporating positional uncertainties of organs.

Materials and Methods: Biologically based mathematical models for describing the relationships between tumour control probability (TCP) and normal-tissue complication probability (NTCP) vs. dose were used to describe some of the results available in the literature. The values of the model parameters were then used together with the value of 1.5 Gy for the prostate cancer alpha/beta ratio to predict the responses in a hypofractionated 3 Gy/fraction IMRT trial at the Christie Hospital, taking into account patient movement characteristics between dose fractions.

Results: Compared with the current three-dimensional conformal radiotherapy technique (total dose of 50 Gy to the planning target volume in 16 fractions), the use of IMRT to escalate the dose to the prostate was predicted to increase the TCP by 5%, 16%, and 22% for the three dose levels, respectively, of 54, 57, and 60 Gy delivered using 3 Gy per fraction while keeping the late rectal complications (>/=Grade 2 RTOG scale) at about the same level of 5%. Further increases in TCP could be achieved by reducing the uncertainty in daily target position, especially for the last stage of the trial, where up to 6% further increase in TCP should be gained.

Conclusions: Dose escalation to the prostate using IMRT to deliver daily doses of 3 Gy was predicted to significantly increase tumour control without increasing late rectal complications, and currently this prediction is being tested in a clinical trial.

Publication

Amer AM, Mott J, Mackay RI, Williams PC, Livsey J, Logue JP, et al. Prediction of the benefits from dose-escalated hypofractionated intensity-modulated radiotherapy for prostate cancer. International Journal of Radiation Oncology Biology Physics 2003; 56: 199-207.

Top of page

W3C XHTML 1.0 logo
W3C CSS logo
Triple-A conformance icon, W3C-WAI Web Content Accessibility Guidelines 1.0
Internet Content Rating Association logo

Regional Medical Physics Department, Freeman Hospital, Newcastle upon Tyne, NE7 7DN, UK.
Tel: +44 (0)191-233-6161 E-mail: webmaster@rmpd.org.uk Web: http://www.rmpd.org.uk
By using this site you agree to our Terms and Conditions of Use. Please read our legal page.
Regional Medical Physics Department, a Clinical Directorate of the Newcastle upon Tyne Hospitals NHS Foundation Trust.
Copyright ©1999-2008 All Rights Reserved. Revised 7 November, 2008.

This Web Site

Accessibility | Feedback | Help | Links | Site Map | What's New |

Our Organisation

FAQs | Find Us | News & Events | Services | Work For Us |

Our Research

Abstracts | Innovation | Publications | What We Do |

Quick Site Search

Advanced search